Skip to main content

From the helm: Botanix Phamaceuticals (ASX:BOT) CEO, Dr Howie McKibbon

Bell Direct
October 9, 2024

In this episode of our From the helm series, Bell Direct’s Grady Wulff speaks with Dr. Howie McKibbon, CEO of Botanix Pharmaceuticals (ASX:BOT). Based in Philadelphia, Botanix is a dermatology company focused on advancing its lead product, Sofdra, which is FDA-approved for the treatment of primary axillary hyperhidrosis. With the successful commercialisation of Sofdra, the company is positioned in a growing market.

Dr. McKibbon joins us to discuss the latest developments and outlook for Botanix,. In this conversation, he covers:

  • (0:42) an overview of Botanix Pharmaceuticals for investors who may not be familiar with the company
  • (1:28) the significance of Sofdra’s FDA approval and the global market potential for its treatment
  • (2:48) the competitive landscape within the dermatology space
  • (3:45) how Botanix manages costs during the later stages of clinical trials and the factors contributing to its financial strength
  • (4:30) insights into what the next 12 months hold for Botanix.

Note: This interview was recorded at the ASX Small to Mid-Cap Conference on 25 September 2024.

Market Update

Julia Lee
December 13, 2018

Market Update

Julia Lee
December 5, 2018

Market Update

Julia Lee
December 3, 2018

Market Update

Julia Lee
November 30, 2018

Market Update 28 Nov

Julia Lee
November 29, 2018

November Market Overview

Julia Lee
November 29, 2018

The Spectrum Strategic Income Fund

Bell Direct
November 6, 2018

The Schroder Fixed Income Fund

Bell Direct
November 6, 2018

The Schroder Absolute Return Income Fund

Bell Direct
November 6, 2018

Market Update

Julia Lee
September 21, 2018

Equity Investor 17 September

Julia Lee
September 18, 2018